neuropathic pain
Conditions
Interventions
Cliga Bahrain besylate capsule group:None
Sponsors
The first affiliated hostipal of nanchang university
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.able to understand and voluntarily sign a written informed consent form (ICF); 2.Age >= 18 years old; 3.Patients with a confirmed diagnosis of neuropathic pain combined with medical history, physical examination and necessary ancillary tests, DN4 >= 4 points; 4.First-time use of crisugabalin besilate capsules;
Exclusion criteria
Exclusion criteria: 1.participation in any other clinical study within 30 days prior to screening; 2.other conditions that, in the judgement of the investigator, make participation in this study inappropriate;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in daily NRS scores over 1 week;Change from baseline in pain NRS score at 4 weeks; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in daily NRS score and DSIS score over 4 weeks;Change from baseline in DSIS score at 1 week;Change from baseline in SF-MPQ (with VAS) scores at weeks 1 and 4;Adverse events within 4 weeks; | — |
Countries
China
Contacts
Public ContactDaying Zhang
The first affiliated hostipal of nanchang university
Outcome results
None listed